Disparities in Kidney Transplant Waitlisting, with Syed Ali Husain, MD, MPH


Syed Ali Husain, MD, MPH, discusses the importance of kidney transplantation, waitlisting, and how disparities in access to transplantation should be addressed.

Disparities based on sex, race, ethnicity, and employment status may play a role in the kidney transplant waitlisting process, as highlighted by findings from a recent retrospective cohort study of ≥50,000 patients with end-stage kidney disease on dialysis.1

Using data from the US Renal Data System Registry, investigators identified 52,902 patients aged ≤40 years with no major medical comorbidities who initiated dialysis between January 1, 2005, and December 31, 2019, and examined time to waitlisting for a kidney transplant. Investigators categorized patients into 3 groups based on outcome: waitlisted <1 year after dialysis initiation, waitlisted 1-5 years after dialysis initiation, or not waitlisted within 5 years of dialysis initiation.1

In total, 15,840 (30%) patients were waitlisted within 1 year, 11,122 (21%) between 1-5 years, and 25,940 (49%) patients were not waitlisted within 5 years of dialysis initiation. Investigators noted sex and age impacted waitlisting, with increased age (subhazard ratio [SHR], .98 per year; 95% confidence interval [CI], .97 to .98; P < .001) and female sex (SHR, .92; 95% CI, .90 to .94; P <.001) associated with decreased waitlisting. Hispanic ethnicity (SHR, .77; 95% CI, .75 to .80; P < .001), Black race (SHR, .66; 95% CI, .64 to .68; P < .001), and unemployment (SHR, .47; 95% CI, .45 to .48; P < .001) were also associated with reduced waitlisting.1

The editorial team of HCPLive Nephrology sat down with primary investigator Syed Ali Husain, MD, MPH, assistant professor of medicine at Columbia University Medical Center, for more insight into chronic kidney disease, study results, and how waitlisting disparities can be improved moving forward.

Recent Videos
1 KOL is featured in this Insights series.
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Discussing Post-Hoc Data on Ruxolitinib for Nonsegmental Vitiligo, with David Rosmarin, MD
1 KOL is featured in this series.
1 KOL is featured in this series.
© 2024 MJH Life Sciences

All rights reserved.